Brief: Actinium Signs Research And Development Agreement With National Cancer Institute For Blood Cancer Treatment
06/02/2023 15:54
Feb 6 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM SIGNS COOPERATIVE RESEARCH AND DEVELOPMENT
AGREEMENT
WITH NATIONAL CANCER INSTITUTE TO FURTHER ENHANCE CLINICAL AND
NON-CLINICAL DEVELOPMENT OF ACTIMAB-A FOR THE TREATMENT OF ACUTE
MYELOID LEUKEMIA AND OTHER HEMATOLOGIC MALIGNANCIES
Source text for Eikon: ID:nPn5cz8Npa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities